Idenix Pharmaceuticals LLC
(NASDAQ : IDIX)

( )
IDIX After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson
1.18%131.650.7%$952.19m
PFEPfizer Inc.
0.49%36.690.9%$757.40m
MRKMerck & Co., Inc.
1.43%85.170.7%$678.51m
ABBVAbbVie, Inc.
0.99%72.382.3%$543.60m
BMYBristol-Myers Squibb Company
0.98%50.561.4%$467.46m
LLYEli Lilly and Company
1.59%116.171.0%$379.52m
AZNAstraZeneca PLC Sponsored ADR
1.28%45.181.2%$146.91m
NVSNovartis AG Sponsored ADR
0.79%87.030.2%$130.76m
GSKGlaxoSmithKline plc Sponsored ADR
0.75%41.630.3%$85.05m
NVONovo Nordisk A/S Sponsored ADR Class B
2.02%52.930.1%$78.51m
SNYSanofi Sponsored ADR
3.43%46.460.2%$61.74m
LCILannett Company, Inc.
2.83%13.7935.6%$53.98m
AKTXAkari Therapeutics Plc Sponsored ADR
0.52%1.941.6%$2.11m
EPIXESSA Pharma Inc
-6.23%2.860.1%$0.19m

Company Profile

Idenix Pharmaceuticals LLC is a biopharmaceutical company, which is engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and France. Currently, its primary research and development focus is on the treatment of patients with hepatitis C virus, or HCV, using nucleotide polymerase inhibitors and NS5A inhibitors. Idenix Pharmaceuticals was founded by Jean-Pierre Sommadossi and Raymond F. Schinazi in May 1998 and is headquartered in Cambridge, MA.